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Abstract 1 
Objectives. Melatonin levels decrease physiologically with age, and possibly with the transition to 2 
menopause. The plausible influence of hormone therapy (HT) on melatonin is poorly understood. 3 
The aim of this randomized, placebo-controlled, double-blind trial was to investigate the effect of 4 
HT administration on serum melatonin concentrations in late premenopausal and postmenopausal 5 
women. Study design. Analyses were carried out among 17 late premenopausal and 18 6 
postmenopausal healthy women who participated in a prospective HT study in Finland. Serum 7 
melatonin was sampled at 20-minute (21:00-24:00 h; 06:00-09:00 h) and one-hour (24:00-06:00 h) 8 
intervals at baseline and after six months with HT or placebo. Main outcome measures. Melatonin 9 
levels and secretion profile after six months of HT compared to placebo. Results. Mean melatonin 10 
levels, mean melatonin exposure level (area under curve, AUC) and mean duration of melatonin 11 
secretion did not differ after six months with HT vs. placebo, irrespectively of the reproductive 12 
state. However, in postmenopausal women the melatonin peak time (acrophase) was delayed by 2.4 13 
hours (2 h 21 min) on average after six months with HT vs. placebo (p<0.05). No interaction 14 
between time and group was detected when melatonin level was modelled before or after treatment. 15 
Conclusions. Administration of HT to postmenopausal women alters melatonin peak time, but not 16 
melatonin levels. Further research on larger clinical samples is needed to better understand the 17 
effects of HT on melatonin profile. 18 
Keywords: acrophase, hormone replacement, late premenopause, postmenopause, reproduction19 
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1. Introduction 1 
Melatonin is a hormone produced by the pineal gland and, in smaller amounts, in peripheral sites 2 
including the retina, skin and the gastrointestinal tract [1]. Its synthesis starts from the serotonin 3 
precursor, tryptophan, and is strongly regulated by the light-dark transitions, with light having an 4 
inhibitory effect [2]. Specifically, melatonin production and secretion follow a circadian rhythm, 5 
increasing about two hours before the sleep onset, peaking during the night and decreasing in the 6 
early morning.   7 
Although with conflicting results, animal and human studies suggest that female gonadal hormones 8 
contribute to the modulation of melatonin production [3,4]. Specifically, several animal studies 9 
have found a reduced melatonin synthesis and secretion in association with high oestrogen levels 10 
[5-9], while others have reported an oestrogen-mediated stimulation of melatonin receptor 11 
activation in rats and hamsters [10,11], and a stimulation of melatonin synthesis and release in rat 12 
pinealocytes following oestrogen exposure [4]. Similarly, high levels of progesterone (either 13 
endogenous, during the luteal phase of the menstrual cycle, or exogenous as in combined oral 14 
contraceptives) were associated with high melatonin levels in women [12,13]. In general melatonin 15 
levels seem to vary in connection with reproductive events. For example, despite inconsistencies 16 
regarding the associations with menstrual cycle phases [12,14-20], healthy pregnant women were 17 
found with higher melatonin levels than postpartum women [21]. Probably as a consequence of 18 
higher gonadal hormone levels, melatonin exposure levels increased with the number of weeks 19 
during pregnancy [21] and, contrary to the duration of secretion and the offset timing, positively 20 
correlated with oestrogen and progesterone levels [22]. As opposite associations were found in 21 
depressed pregnant women, the authors suggested that the sensitivity to the modulating effects of 22 
oestradiol on melatonin receptors may be impaired in depression [21,22].  23 
Further indirect support to the hypothesis of potential associations between melatonin and 24 
reproductive hormones comes from research on the modulation of circadian rhythms by gonadal 25 
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steroids [23]. In fact, melatonin can be considered one of the best measures of circadian clock 1 
functions in humans [24]. On the basis of these studies, oestrogens are deemed to advance circadian 2 
rhythms (reflected in the timing of sleep onset) and shorten circadian periods [25-27], while 3 
progesterone may phase-delay [28] circadian rhythms. In this context, it would be plausible to 4 
hypothesize that in conditions of relatively high levels of gonadal steroids (such as in the 5 
premenopause), melatonin rhythms would be more phase-advanced, whereas in conditions, such as 6 
postmenopause, where there is a decline in gonadal steroids, rhythms would be more phase-delayed. 7 
However, as age is as such associated with a decreased hypothalamic sensitivity to oestrogens [29], 8 
it is possible that aging causes a reduced phase-shift response to gonadal steroids. In addition, peak 9 
levels, as well as the total amount of melatonin, are known to decrease physiologically with age 10 
[30,31]. Partly as a consequence of this, melatonin levels are lower in postmenopausal women when 11 
compared with both premenopausal and perimenopausal women [32,33]. It is likely that the 12 
menopause-related hormonal changes, alone or in combination with age, contribute to this decline. 13 
With this respect, a transient increase in melatonin levels has been described in connection with the 14 
transition to menopause, whether natural or surgical [34]. However, melatonin levels have been 15 
observed to subsequently decline after the beginning of menopause [34]. 16 
 17 
We have previously shown that the mean overnight melatonin concentration and exposure level 18 
(AUC, i.e. area under nocturnal melatonin curve), as well as the duration of secretion, are lower in 19 
postmenopausal than in perimenopausal women [33]. Administration of hormone therapy (HT) after 20 
the menopause is known to restore the female gonadal hormone levels and is commonly used to 21 
alleviate climacteric symptoms in peri- and postmenopausal women; additionally, it is also effective 22 
in controlling early symptoms in premenopausal women. Nevertheless, to date only a few studies 23 
have addressed the question whether HT, either as unopposed oestrogen treatment (ET) or 24 
combined oestrogen-progesterone treatment (EPT), may also influence serum melatonin levels. 25 
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Even with some inconsistencies [35], their main findings have been those of a reduction in 1 
nocturnal [34] or diurnal [36] melatonin levels after oestrogen or progesterone [5] administration in 2 
postmenopausal women.  3 
 4 
The aim of this prospective, randomized, placebo-controlled, double-blind study was therefore to 5 
investigate the effect of HT (specifically EPT, which is the most commonly used form in clinical 6 
practice) on melatonin levels and secretion profile in late premenopausal and postmenopausal 7 
women. As gonadal steroids are known to influence the levels and secretion profile of melatonin, 8 
and as the menopausal-related reduction of gonadal hormones may be associated with a reduction in 9 
melatonin levels in postmenopause, we hypothesized that 6-month treatment with HT could restore 10 
serum melatonin levels of postmenopausal women to late premenopausal levels. 11 
 12 
2. Methods 13 
2.1 Subjects 14 
Seventeen late premenopausal (mean age = 47.7 years; SD = 2.2; range = 43-51 years) and 18 15 
postmenopausal (mean age = 63.4 years; SD = 3.6; range = 58-71 years) women were recruited to 16 
participate in a prospective study aimed to evaluate the effects of aging and HT on sleep and 17 
cognition as well as on melatonin secretion. The recruitment procedure consisted of advertisements 18 
in the local newspapers in the area of Turku, Finland. The reproductive state was defined as late 19 
premenopausal, if serum FSH levels were lower than 23 IU/ml and the subject had ongoing regular 20 
or irregular menstrual cycle, whereas postmenopausal women were defined by age (≥58 y) and 21 
chronic amenorrhea more than one year. Women having a mental, cardiovascular (except drug-22 
treated balanced hypertension), endocrine (except drug-treated balanced hyperlipidaemia), 23 
pulmonary, neurological or specific sleep disorder (like sleep apnoea or restless legs); malignancies; 24 
or other conditions possibly affecting sleep (e.g. fibromyalgia, anaemia) were excluded. Alcohol 25 
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abuse, smoking, excessive caffeine intake (>5 cups per day) and use of other substances that affect 1 
the central nervous system were additional exclusion criteria. The subjects kept a sleep diary in the 2 
three weeks before and one week after the study to verify their sleep-wake schedules; all women 3 
had regular sleep-wake schedules (22:00-23:00 h to 6:00-7:00 h). Women were ensured to have 4 
normal levels of blood haemoglobin, leucocytes, thrombocytes and serum thyrotropin before 5 
enrolment on the study. One late premenopausal woman and 13 postmenopausal women had 6 
previously used HT. A washout period of at least 12 months was required. More details about the 7 
data collection and study design have already been described elsewhere [37]. After receiving oral 8 
and written information, all women gave written informed consent. The study was registered as a 9 
European Research Project (QLK6-CT-2000-00499) and approved by the Ethics Committee of 10 
Turku University Hospital and the University of Turku, Finland. The study was carried out in 11 
accordance with the Declaration of Helsinki. 12 
 13 
2.2 Study design 14 
The randomized, placebo-controlled, double-blind study consisted of a baseline phase followed by a 15 
6-month follow-up assessment. At baseline, the women spent three nights (one adaptation night 16 
from 19:30 h to 8:00 h, and two sleep-recording nights, the first one from 19:30 h to 12:00 h and the 17 
second one from 19:30 h to 21:00 on the next day) in the sleep laboratory at the University of 18 
Turku, Sleep Research Unit. The women went to bed (lights-off) at 23:00 h, and were woken up 19 
(lights-on) at 7:00 h. During the night only red light was allowed for illumination if needed. During 20 
the third evening an intravenous catheter was inserted into the forearm and blood was drawn every 21 
20 minutes for 24 hours, starting at 21:00 h. At night (21:00 h to 7:00 h.) the catheter was connected 22 
to a plastic tube extending into an adjacent room to allow repeated blood sampling with minimal 23 
disturbance of the subject’s sleep. Between 21:00 h and midnight as well as between 6:00 h to 9:00 24 
h melatonin measurements were available from 20-minute interval samples, and between midnight 25 
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and 6:00 h from one-hour interval samples. The blood samples were drawn into EDTA tubes, 1 
placed in the refrigerator for 20 minutes, centrifuged, frozen immediately and stored at -70°C until 2 
assayed. Samples were assayed for melatonin by radioimmunoassay with an iodinated melatonin 3 
tracer and a melatonin-specific antiserum [38]. The lowest detectable concentration by the method 4 
was 1.3 pg/ml (5.7 pmol/l), and the intra-assay and inter-assay coefficients of variation were from 5 
6.7 to 9.5% and from 9.8 to 12.5%, respectively. 6 
 7 
In the second step, the women were randomized to HT or placebo for a 6-month period. 8 
Randomization was performed in 6-person blocks at the pharmacy of the Turku Central University 9 
Hospital, where the randomization codes were kept until completion of the study, so that all the 10 
persons involved in the study were blinded to interventions. Nine late premenopausal women were 11 
given cyclic EPT (2 mg oestradiol valerate for 16 days and 2 mg oestradiol valerate + 1 mg 12 
norethisterone for 12 days, Mericomb®, Novartis, Basel, Switzerland), and 8 were allocated to 13 
placebo. Administration started on day 1 of their menstrual cycles. One of the late premenopausal 14 
women in the EPT group dropped-out for personal reasons after randomization. Nine 15 
postmenopausal women received continuous EPT (2 mg oestradiol valerate + 0.7 mg 16 
norethisterone, Merigest®, Novartis, Basel, Switzerland), and nine were allocated to placebo. All 17 
postmenopausal women completed the follow-up. The subjects underwent a 3-month check-up, 18 
where the compliance to the treatment was checked through an interview and assessment of serum 19 
FSH and E2 levels, and side-effects of the treatment were recorded. The blood tests showed that all 20 
women were compliant to the treatment. At the end of the 6-month treatment period the participants 21 
returned to the sleep laboratory to repeat the sleep studies and blood sampling protocol identically 22 
to baseline. The follow-up study was carried out at three months for one, at four months for two and 23 
at five months for a fourth postmenopausal woman of the HT group, mainly due to side-effects 24 
(bloating, uterine bleeding). One postmenopausal woman from the placebo group attended the 25 
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follow-up study after four months of treatment, and another developed a venous thrombosis of the 1 
eye, shortening the treatment period to five months. All late premenopausal women were examined 2 
in the beginning of their menstrual cycle both at baseline (in the follicular phase) and after treatment 3 
(on opposed oestrogen). Altogether thirty-four women completed the study; after the study three 4 
postmenopausal women from the placebo group were excluded from the analyses because of 5 
incomplete melatonin data (Figure 1). The study continued for 29 months. Blood samples were 6 
collected all throughout the year. In detail, 5 of the late premenopausal women in the HT group and 7 
5 in the placebo group had their baseline evaluation during winter time (October to March) and the 8 
after-treatment assessment during summer time (April to September); additionally, 1 late 9 
premenopausal woman in the HT group had both baseline and after-treatment assessments during 10 
winter time, while the remaining 5 women were first studied during summer and re-assessed during 11 
winter time. Similarly, 5 of the postmenopausal women in the HT group and 3 in the placebo group 12 
were studied during winter time at baseline and in summer time at the end of the treatment. Of the 4 13 
remaining women in the HT group, 2 were first studied during summer and re-assessed during 14 
winter time, 1 had both baseline and after-treatment assessments during winter time and 1 during 15 
summer time; in the placebo group, 2 were first studied during summer and re-assessed during 16 
winter time, and 1 had both baseline and after-treatment assessments during summer time. 17 
However, during the study period, the participants spent their time inside the building, in a dark 18 
room without windows, with strictly controlled night-time illumination levels; this limited the 19 
possible influence of different photoperiods on the participants. 20 
 21 
2.3 Questionnaires 22 
In order to guarantee that the groups were similar in their symptoms profiles, several questionnaires 23 
were included at baseline and follow-up assessments. Climacteric vasomotor symptoms were scored 24 
with two questions on the past six months (night sweats and hot flashes). The frequency of the 25 
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symptoms was determined on the following four-point scale: one (“seldom or never”), two 1 
(“approximately once a month”), three (“approximately once a week”), four (“almost every day”). 2 
Vasomotor symptom score was calculated as a sum of the two scores. Depression during the past 3 
four weeks was evaluated with the Beck Depression Inventory (BDI, a sum score, with the range of 4 
0-63) [39], and current anxiety with the State-Trait Anxiety Inventory (STAI, a sum score, with the 5 
range of 20-80) [40]. Insomnia and sleepiness during the past three months were evaluated using the 6 
Basic Nordic Sleep Questionnaire (BNSQ) [41]. The variables were sum scores in the range of 5-7 
25, where a low score indicated good sleep or a low level of sleeping problems and sleepiness. The 8 
subjective sleep quality of the preceding night (Subjective Sleep Score) was inquired in the morning 9 
by questions on sleep quality, sleep efficiency, sleep latency, number of awakenings, too early 10 
morning awakening and morning tiredness, with a lower score indicating better sleep or a low level 11 
of sleeping problems (range = 6-20). The quality of life (an index score, with the range of from -12 
0.011 to +1) was assessed with the EuroQoL quality of life questionnaire (EQ-5D; an index score, 13 
ranging from -0.011 to +1) and the EQ-5D visual analogy scale (VAS, range = 1-100) [42]. The 14 
EQ-5D index was calculated through a specific algorithm which considers a weight for each 15 
dimension [43]. All the questionnaires were completed at baseline and at the end of the treatment 16 
period. 17 
 18 
2.4 Statistical analysis 19 
Normality of the distribution was tested with Kolmogorov-Smirnov test, after which bivariate 20 
analyses were performed to study the differences between the groups using Student's t-test or 21 
Wilcoxon rank-sum test. A p-value of <0.05 was considered as significant. The two-sample t-test or 22 
the Wilcoxon rank sum test was used to compare HT vs. placebo groups, both at baseline and after 23 
treatment, separately within late premenopausal and postmenopausal women. First, the nocturnal 24 
melatonin exposure curve was interpolated and smoothed curves were produced; thereafter, the area 25 
10 
 
under melatonin exposure curve (AUC) (from lights-off to lights-on) was calculated for each 1 
subject. For each group mean, quartiles and median values of melatonin exposure were calculated. 2 
Any change in melatonin exposure after HT/placebo was calculated by means of differences (after 3 
treatment vs. baseline), and analysis of variance was performed to test the significance of the 4 
changes in HT vs. placebo groups. Mixed regression models were used to disentangle the effect of 5 
age and reproductive state on melatonin exposure. The peak time of melatonin secretion (acrophase) 6 
and the duration of time when melatonin levels were ≥10 pg/ml were calculated for each group, and 7 
the differences between groups were tested by Wilcoxon rank-sum test. Additionally, correlations 8 
between the changes in melatonin peak time and in sleep quality after HT/placebo (after treatment 9 
vs. baseline) were calculated. In order to study the melatonin measurement profiles, repeated 10 
measurements of melatonin levels during night were modelled using a mixed-effect model with the 11 
individual as a random effect, and group (randomization) and time (starting from lights-off) as fixed 12 
explanatory variables [44]. Time was modelled using natural splines (with df=4). Interaction 13 
between time and group was tested using log-likelihood test. All the statistical analyses were 14 
performed using SPSS/PASW software (version 18.0) (SPSS Inc., Chicago, IL, USA) and R [45]. 15 
 16 
3. Results 17 
At baseline melatonin levels were lower in postmenopausal women compared to late 18 
premenopausal women (mean serum melatonin levels: 16.9 pg/ml (SD 7.9) vs 24.6 pg/ml (SD 19 
10.0), p=0.015) [33]. After randomization to HT or placebo, four groups were defined (late 20 
premenopausal HT and placebo groups, and postmenopausal HT and placebo groups). Within each 21 
reproductive group (late premenopausal and postmenopausal), at baseline the HT and placebo 22 
groups did not differ in respect to FSH levels, E2 levels, climacteric vasomotor symptoms, BDI 23 
scores, STAI scores, BNSQ insomnia or sleepiness scores, subjective sleep score or EQ-5D (Table 24 
1). At baseline melatonin levels (mean, maximum, minimum), exposure levels (AUC) and peak 25 
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time (acrophase), as well as the duration of melatonin levels ≥10 pg/ml did not differ between HT 1 
and placebo within the reproductive groups (Table 2; Figures 2 and 3). 2 
 3 
At the end of the treatment period FSH levels were lower and E2 levels higher in HT group 4 
compared to the placebo group; however, this finding was limited to the postmenopausal women 5 
(late premenopausal: FSH=10.4 vs. 9.4 IU/l, SD=5.5 vs. 5.0, p=0.674; and E2=226.4 vs. 247.8 6 
pmol/l, SD=129.2 vs. 70.9, p=0.115; postmenopausal: FSH=11.6 vs. 72.3 IU/l, SD=11.1 vs. 19.4, 7 
p<0.001; and E2=193.0 vs. 29.6 pmol/l, SD=65.9 vs. 13.8, p<0.001). The symptom profiles did not 8 
differ between the groups (data not shown). No difference was found in mean melatonin levels, 9 
mean melatonin exposure level (AUC) and mean duration of melatonin secretion (Table 3; Figures 10 
2 and 3). However, in postmenopausal women the melatonin peak time was delayed by 2.4 hours in 11 
the HT group compared to placebo group at the end of the treatment (05:12 h vs. 02:51 h, p=0.011); 12 
on the contrary, late premenopausal women had a non-significantly advanced acrophase after 6-13 
month HT than after 6-month placebo (03:42 h vs. 04:45 h, p=0.195). Changes in melatonin 14 
exposure after six months of HT or placebo in comparison with baseline were calculated separately 15 
for late premenopausal and postmenopausal women: no significant difference emerged (Table 4). 16 
Further, an analysis of variance was performed to test whether the changes in melatonin exposure 17 
after six months of HT vs. six months of placebo differ, after controlling for age, body-mass index 18 
(BMI) and reproductive state, but the analysis produced no significant results. In additional linear 19 
mixed models (HT/placebo, age, BMI and reproductive state as predictors) no significant 20 
associations were gained. No significant interaction between time and group was detected when 21 
melatonin level was modelled before or after treatment, suggesting that HT did not affect the level 22 
of melatonin secretion (data not shown). 23 
 24 
4. Discussion 25 
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The main finding of this study is the lack of significant influence of HT on serum melatonin levels 1 
in postmenopausal and in late premenopausal women. Furthermore, this is the first study to show 2 
that HT may alter melatonin peak time (acrophase), and in specific, that HT may delay the 3 
melatonin peak time after menopause without any other changes in the levels of melatonin 4 
secretion, and independently of age and BMI.  5 
 6 
To date, the literature has produced sparse findings regarding the effects of HT on melatonin 7 
secretion. Bartsch et al. [35] found that the effect of unopposed ET on melatonin levels in 8 
postmenopausal women depended on the route of administration: after oral oestrogen 9 
administration there was a trend for higher melatonin levels, but after transdermal oestrogen 10 
administration the melatonin levels were lower. However, when analysing the individual melatonin 11 
secretion profiles, because of the high inter-individual variability, the route of oestrogen 12 
administration did not predict the profile of melatonin secretion. Similarly, Kerdelhué et al. [46] 13 
reported only a tendency toward a decline in melatonin levels after a single injection of conjugated 14 
oestrogen after menopause, and Kos-Kudla et al. [36] found a reduction of daily melatonin secretion 15 
after six months of EPT in postmenopausal women, with no effect on overall melatonin circadian 16 
rhythm. Also, ET has been found not to affect melatonin measures in healthy women [47], even 17 
though a combined EPT advanced melatonin onset in healthy women, and oestrogen and 18 
antidepressant in combination reduced melatonin levels in menopausal depressed women [47], who 19 
have generally higher melatonin secretion levels and delayed offset compared to non-depressed 20 
peri- and postmenopausal women [47,48]. This, though limited, lack of evidence for any strong 21 
influence of HT on melatonin measures is consistent with our results, which showed no difference 22 
in melatonin exposure levels. Moreover, even when controlling separately for the effect of age vs. 23 
reproductive state, we did not find any significant changes. Similarly, we did not find any 24 
interaction between time and group when the melatonin level was modelled before or after 25 
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treatment, providing more evidence for the lack of general effect of HT on serum melatonin 1 
concentrations.  2 
However, we cannot rule out that this lack of association is a consequence of the high inter-3 
individual variability in the levels of melatonin, typically found in middle and old age. In general, 4 
there seems to be a significant inter-individual variation in melatonin secretion in adulthood, while 5 
it is known that melatonin production and the amplitude of its rhythm decrease with age [30,49], as 6 
a consequence of higher daytime levels and lower night-time levels in the elderly. When analysing 7 
the profile of 24-hour salivary melatonin rhythm in different age groups, Zhou et al. [50] found the 8 
lowest melatonin amplitude in subjects aged 41-53 years, who also had the longest duration of 9 
melatonin secretion. However, they found higher levels of daytime salivary melatonin, and more 10 
variability in melatonin rhythms in old compared with young and middle-age subjects. These data 11 
suggest that the alteration in the profile of melatonin secretion starts already in middle age. 12 
 13 
In general, HT has been shown to alleviate several climacteric symptoms, such as vasomotor 14 
symptoms, as well as sleep and mood problems [51,52]. Since in our study melatonin levels, 15 
exposure levels or duration of secretion were not altered by HT administration, it seems plausible to 16 
infer that the beneficial effects of HT are not mediated by influences on quantitative melatonin 17 
secretion. Rather, the benefits of HT could be related to its influence on melatonin timing 18 
(acrophase).  19 
We have earlier found that the peak time of melatonin secretion is similar between postmenopausal 20 
women and perimenopausal women without HT [33]. However, in the current study we have shown 21 
that the effects of HT on melatonin acrophase differed in postmenopausal women compared to late 22 
premenopausal women. In specific, HT was associated with a delay in melatonin acrophase in 23 
postmenopausal women only. This finding is a novel one. It has been previously reported that the 24 
salivary melatonin acrophase is advanced in postmenopausal compared with premenopausal women 25 
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[53]. Thus, if melatonin acrophase tends to be advanced during menopause, we could speculate that 1 
administration of HT could, partly or totally, counteract this process. However, again the previously 2 
published data are inconsistent. While Sharma et al. [54] reported a positive correlation between the 3 
plasma melatonin acrophase and age, Zhou et al. [50] found no significant difference in the salivary 4 
melatonin acrophase in different age groups, even though middle-aged subjects (41-53 years) 5 
tended to have a delayed acrophase compared with both younger and older subjects. As according 6 
to Zhou et al. [50] the most relevant alterations in melatonin secretion profile are found in middle-7 
aged subjects, it could be hypothesized that the menopausal transition is associated with a transient 8 
delay in the melatonin acrophase which would naturally return to more advanced values later after 9 
the menopause is entered. Thus, administration of HT to postmenopausal women would alter the 10 
melatonin acrophase towards values closer to those of the preceding reproductive phase, i.e. to a 11 
delayed acrophase as shown in women with own ovarian hormone production. On the contrary, 12 
administration of HT during late premenopause could affect the melatonin acrophase towards early 13 
premenopausal profiles. This is further supported by the evidence that in our study late 14 
premenopausal women had a tendency to an earlier acrophase after 6-month HT than after 6-month 15 
placebo. This would be in line with the hypothesis that the decline in gonadal steroids may be 16 
associated with delayed circadian rhythms, where HT could contribute to restore more advanced 17 
rhythms. However, as mentioned above, aging reduces the sensitivity to oestrogens, this possibly 18 
explaining our finding of delayed peak time in (old) postmenopausal women after HT. In this 19 
context, the delayed peak time in postmenopausal women could be mostly due to the progestogenic 20 
component of the HT. However, again it must be noticed that the high inter-individual variability in 21 
melatonin levels within the study subjects may have confounded the precise detection of the 22 
melatonin acrophase, in particular in late premenopausal women. 23 
 24 
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The interpretation of our present finding and its clinical implications are not unambiguous. The 1 
earlier body of literature has produced inconsistent findings on the association between the 2 
melatonin acrophase and health status. It seems that the melatonin acrophase correlates with mood 3 
in women, and that those with a more phase-advanced acrophase have more positive affects [55]. 4 
With respect to mood disorders the associations are even more inconsistent. In the case of seasonal 5 
affective disorder [56], Checkley et al. [57] found no acrophase differences, while, according to the 6 
“phase-shift hypothesis”, seasonal affective disorder associates with a phase delay of circadian 7 
rhythms, including that of melatonin [58]. Similarly, a trend toward a delayed serum melatonin 8 
acrophase was reported in depressed patients [59], while other studies have observed an advanced 9 
(or a trend toward an advanced) plasma/serum melatonin peak in depression [60,61], or no 10 
associations between peak time of the urinary melatonin metabolite 6-sulfatoxymelatonin and 11 
current depression in the elderly (60-78 years) [62]. Finally, postmenopausal women with MDD 12 
(major depressive disorder) exhibited a tendency for delayed urinary melatonin metabolite 13 
acrophase compared with healthy postmenopausal women [63]. In the same study, an association 14 
was detected between delayed acrophase and lifetime MDD. Our results show that HT in 15 
postmenopausal women may contribute to change the melatonin peak time; this suggests that the 16 
beneficial effects of HT may partly be mediated by alterations (possibly normalization) of circadian 17 
rhythms, as melatonin is among the best measures of circadian rhythms in humans. If this is the 18 
case, it would have specific clinical implications for women suffering from sleep problems or 19 
depression during the menopause, especially with seasonal features. However, further research with 20 
longitudinal design is needed to better understand the effects of delayed or advanced melatonin 21 
peak time on mood and its relationships with HT.  22 
 23 
4.1 Strengths and limitations of the study 24 
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In our study melatonin assessment was based on a repeated serum sampling technique, which is the 1 
best technique to measure melatonin phase, duration and amplitude, in particular when frequent, i.e. 2 
every 20-30 minutes, samples are taken [64]. Additionally, the high-frequency collection of serum 3 
samples under strictly controlled sleep laboratory conditions ensured the good quality of the 4 
samples. Furthermore, the randomized, double-blind, prospective design conferred additional 5 
validity to the study, and the strict exclusion criteria allowed us to exclude several confounding 6 
factors. As melatonin levels decrease with aging [30,31] and may be affected by BMI [65], we 7 
controlled our results by age and BMI. The time effect, which is crucial in repeated analyses, was 8 
also ruled out. In addition, we controlled the symptom profiles of the women by a large set of 9 
questionnaires in order to guarantee that the possible effects of HT on melatonin secretion were not 10 
influenced by differences in symptom profiles. 11 
 12 
The main limitation of our study is the small sample size. Also, as mentioned above, the study was 13 
carried out on a generally healthy population, preventing the generalization of the results to larger 14 
populations with common chronic diseases. The melatonin sampling took place throughout the year, 15 
thus possibly influencing the results (a seasonal effect). However, during their visit in the sleep 16 
laboratory the women spent their time inside the building and the night-time illumination levels 17 
were strictly controlled. Also, the high inter-individual variability in melatonin levels prevented 18 
from calculating additional measures of melatonin secretion profile, such as the synthesis offset and 19 
midpoint time.  20 
 21 
4.2 Conclusions 22 
Our results suggest that HT may delay the melatonin peak time (acrophase) in postmenopausal 23 
women, without other effect on the melatonin rhythm. Further research on larger clinical 24 
17 
 
populations is needed to better understand the effects of HT on melatonin secretion profile and its 1 
possible interaction especially with mood and sleep quality. 2 
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Figure 1. Flow chart of the study design. 1 
 2 
Figure 2. Overnight mean melatonin levels at baseline and at the end of the treatment period 3 
in late premenopausal women: HT vs. placebo.  4 
 5 
 6 
Figure 3. Overnight mean melatonin levels at baseline and at the end of the treatment period 7 
in postmenopausal women: HT vs. placebo.  8 
 9 
 10 
11 
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Table 1. Baseline hormone and health score values of late premenopausal and postmenopausal HT 1 
vs. placebo groups. 2 
 Late premenopausala Postmenopausala 
 HT  
mean (SD) 
Placebo  
mean (SD) 
HT  
mean (SD) 
Placebo  
mean (SD) 
s-FSH (IU/l) 12.3 (5.4) 9.9 (3.9) 69.9 (41.0) 78.9 (29.4) 
s-E2 (pmol/l) 442.9 (442.9) 159.0 (102.1) 34.5 (12.4) 33.2 (12.6) 
Climacteric symptoms score 2.7 (1.0) 2.9 (1.0) 4.9 (2.6) 3.4 (2.2) 
BDI score 3.7 (2.6) 4.0 (3.6) 5.7 (4.1) 6.9 (4.3) 
STAI score 44.8 (3.0) 42.8 (4.4) 43.8 (2.9) 44.1 (3.6) 
BNSQ insomnia score 13.0 (4.0) 14.0 (2.6) 15.2 (4.9) 16.8 (2.8) 
BNSQ sleepiness score 9.0 (2.7) 12.6 (4.8) 9.4 (3.3) 12.0 (2.3) 
Subjective sleep score  12.1 (2.4) 11.5 (2.7) 12.2 (2.4) 11.1 (1.6) 
EQ-5D index score 0.94 (0.1) 0.90 (0.1) 0.82 (0.2) 0.85 (0.1) 
EQ-5D VAS score 89.5 (5.8) 89.8 (6.5) 80.2 (16.2) 80.3 (7.6) 
at-test/Wilcoxon rank sum test not significant  3 
BDI: Beck Depression Inventory; BNSQ: Basic Nordic Sleep Questionnaire; EQ-5D: EuroQoL quality of life 4 
questionnaire; E2: estradiol; FSH: Follicle Stimulating Hormone; HT: hormone therapy; SD: Standard 5 
Deviation; STAI: State-Trait Anxiety Inventory. 6 
 7 
8 
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Table 2. Melatonin levels at baseline in late premenopausal and postmenopausal women: HT vs. 1 
placebo. 2 
 3 
 Late premenopausal Postmenopausal 
 HT  
n=8 
Placebo  
n=8 
HT   
n=9 
Placebo 
n=8 
Melatonin levels (pg/ml)     
mean (SD) 21.0 (9.8) 27.0 (9.7)a 17.1 (5.8) 16.8 (8.7)a 
maximum range 10.5-63.3 11.0-73.5 18.6-47.0 9.7-56.3 
maximum, mean (SD) 35.1 (18.6) 48.0 (19.5)a 29.1 (9.9) 29.5 (15.2)a 
minimum range 2.4-10.0 4.0-15.4 3.0-8.8 2.5-10.6 
minimum, mean (SD) 6.1 (2.7) 8.1 (3.5)a 5.4 (1.8) 5.3 (2.7)a 
Melatonin exposure (AUC, pg/ml x h)     
1st quartile 5.2 9.0 5.1 3.9 
median 7.4 11.3 5.7 6.5 
mean 8.1 11.5a 6.3 6.6a 
3rd quartile 11.9 14.0 7.4 7.3 
Melatonin peak time (h:min) 04:08 04:28a 04:09 03:50a 
Duration of melatonin levels ≥10 pg/ml  
(hours)  
mean (SD) 
 
 
6.6 (2.4) 
 
 
6.9 (2.4)a 
 
 
6.8 (1.2) 
 
 
6.0 (2.5)a 
a t-test/Wilcoxon rank sum test not significant  4 
 5 
28 
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Table 3. Melatonin levels at the end of the treatment period in late premenopausal and 1 
postmenopausal women: HT vs. placebo. 2 
 3 
 Late premenopausal Postmenopausal 
 HT  
n=8 
Placebo  
n=8  
HT 
n=9 
Placebo 
n=6 
Melatonin levels (pg/ml)     
mean (SD) 22.1 (10.7) 31.7 (23.9)a 15.3 (6.0) 19.0 (13.4)a 
maximum range 6.9-63.7 12.7-175.8 8.8-36.9 7.6-60.6 
maximum, mean (SD) 35.3 (17.8) 52.7 (51.4)a 24.7 (10.6) 30.1  (19.1)a 
minimum range 3.1-13.2 2.7-23.7 2.3-7.0 2.7-12.9 
minimum, mean (SD) 8.9 (3.8) 11.6 (7.3)a 4.4 (1.6) 6.3 (3.7)a 
Melatonin exposure (AUC, pg/ml x h)     
1st quartile 6.4 8.0 4.7 4.2 
median 7.4 10.4 6.5 6.3 
mean  8.4 13.1a 6.1 7.4a 
3rd quartile 12.2 12.0 8.1 9.5 
Melatonin peak time (h:min) 03:42 04:45a 05:12 02:51b 
Duration of melatonin levels ≥10 pg/ml 
(hours) 
mean (SD) 
 
 
6.7 (2.8) 
 
 
7.1 (2.0)a 
 
 
5.6 (2.9) 
 
 
5.5 (3.2)a 
a t-test/Wilcoxon rank sum test not significant 4 
b t-test/Wilcoxon rank sum test significant at p<0.05 5 
 6 
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Table 4. Melatonin exposure (AUC) after HT/placebo, change from baseline. 1 
 2 
 Late premenopausal Postmenopausal 
  HT placebo HT placebo 
Melatonin exposure (AUC, pg/ml x h, change from 
baseline) 
    
1st quartile -0.2 -1.9 -1.2 0.1 
median 0.1 -0.5 -0.5 0.4 
mean 0.4 1.6a -0.3 0.7a 
3rd quartile 0.6 0.9 1.1 2.0 
a t-test not significant 3 
 4 
5 
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Figure 1 1 
2 Late premenopausal 
women 
n = 17 
Postmenopausal 
women 
n = 18 
Baseline sleep recordings for three consecutive nights 
(adaptation, baseline, blood sampling) and blood sample for 
melatonin at 20-minute or one-hour intervals 
Cyclic oestrogen 
plus progestogen 
n = 9 
Placeb
o 
n = 8 
Placeb
o 
n = 9 
Continuous oestrogen 
plus progestogen 
n = 9 
Check-up interview, blood sample for E2 and FSH 
Sleep recordings and blood sampling identical to baseline 
Randomization 
3 months Dropouts 
n = 1 
3 months 
n = 8 n = 8 n = 6 n = 9 
Incomplete 
data n = 3 
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Figure 3 1 
 2 
